Immunohistochemical assay for detecting expression of programmed death ligand 1 (PD-L1) in tumor tissue
US11193937B2 · kind B2 · utility
0Cited by
1References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 22, 2017 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | Dec 15, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present disclosure provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections as detected by immunohistochemical assay using an antibody that specifically binds to PD-L1. The results generated using these processes have a variety of experimental, diagnostic and prognostic applications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.